Quent Capital’s Heron Therapeutics HRTX Stock Holding History

Quent Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,000	Closed	-$68K	–	1344
2022 Q3	$68K	Buy	+16,000	New	+$62.6K	0.01%	464

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Quent Capital's HRTX Position: Q4 2022 in Review

Quent Capital sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 16,000 shares — an estimated $68K sold.

Quent Capital first reported a position in HRTX in Q3 2022 and held it in 1 quarter. The position peaked at $68K in Q3 2022. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Quent Capital reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Quent Capital sold 16,000 Heron Therapeutics shares in Q4 2022, an estimated $68K.
Quent Capital first reported a position in Heron Therapeutics in Q3 2022 and held it in 1 quarter.
Quent Capital's Heron Therapeutics position peaked at $68K in Q3 2022.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Quent Capital's 13F filing for Q4 2022, filed 19 Jan 2023.